Suggested remit: To appraise the clinical and cost effectiveness of brolucizumab within its marketing authorisation for treating diabetic macular oedema.
 
Status In progress
Technology type Medicine
Decision Selected
Process FTA
ID number 3902

Provisional Schedule

Expected publication 31 August 2022

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors Novartis Pharmaceuticals (brolucizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Diabetes UK
  Macular Society
  Royal National Institute of Blind People
Professional groups Royal College of Ophthalmologists
  Royal College of Physicians
Associated guideline groups National Guideline Centre
Associated public health groups None
Comparator companies Alimera Sciences (fluocinolone acetonide intravitreal implant) (confidentiality agreement signed, participating)
  Bayer (aflibercept) (confidentiality agreement signed, participating)
  Novartis Pharmaceuticals (ranibizumab) (confidentiality agreement signed, participating)
  Roche (bevacizumab, faricimab) (confidentiality agreement signed, participating)
  Allergan (dexamethasone intravitreal implant) (confidentiality agreement not signed, not participating)
  Organon Pharma (bevacizumab) (confidentiality agreement not signed, not participating)
  Pfizer (bevacizumab) (confidentiality agreement not signed, not participating)
  Sanofi (aflibercept) (confidentiality agreement not signed, not participating)
  Thornton & Ross (bevacizumab) (confidentiality agreement not signed, not participating)
  Zentiva (bevacizumab) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
28 July 2022 - 11 August 2022 Final draft guidance
26 May 2022 This appraisal is being considered as a Fast Track Appraisal (FTA). If a positive recommendation is made through the FTA process, NHS England/commissioners have committed to providing funding for the technology within 30 days of final guidance publication.
09 February 2022 Invitation to participate
06 October 2021 - 03 November 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 February 2021 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual